Correlation Engine 2.0
Clear Search sequence regions


  • brequinar (7)
  • DHODH (10)
  • ENT1 (8)
  • mice (1)
  • nucleotides (4)
  • pyrimidines (2)
  • Sizes of these terms reflect their relevance to your search.

    Inhibitors of dihydroorotate dehydrogenase (DHODH), a key enzyme for de novo synthesis of pyrimidine nucleotides, have failed in clinical trials for various cancers despite robust efficacy in preclinical animal models. To probe for druggable mediators of DHODH inhibitor resistance, we performed a combination screen with a small molecule library against pancreatic cancer cell lines that are highly resistant to the DHODH inhibitor brequinar (BQ). The screen revealed that CNX-774, a preclinical Bruton tyrosine kinase (BTK) inhibitor, sensitizes resistant cell lines to BQ. Mechanistic studies showed that this effect is independent of BTK and instead results from inhibition of equilibrative nucleoside transporter 1 (ENT1) by CNX-774. We show that ENT1 mediates BQ resistance by taking up extracellular uridine, which is salvaged to generate pyrimidine nucleotides in a DHODH-independent manner. In BQ-resistant cell lines, BQ monotherapy slowed proliferation and caused modest pyrimidine nucleotide depletion, whereas combination treatment with BQ and CNX-774 led to profound cell viability loss and pyrimidine starvation. We also identify N-acetylneuraminic acid accumulation as a potential marker of the therapeutic efficacy of DHODH inhibitors. In an aggressive, immunocompetent pancreatic cancer mouse model, combined targeting of DHODH and ENT1 dramatically suppressed tumor growth and prolonged mouse survival. Overall, our study defines CNX-774 as a previously uncharacterized ENT1 inhibitor and provides strong proof of concept support for dual targeting of DHODH and ENT1 in pancreatic cancer. Copyright © 2022 Elsevier B.V. All rights reserved.

    Citation

    Nicholas J Mullen, Ravi Thakur, Surendra K Shukla, Nina V Chaika, Sai Sundeep Kollala, Dezhen Wang, Chunbo He, Yuki Fujii, Shikhar Sharma, Scott E Mulder, David B Sykes, Pankaj K Singh. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Cancer letters. 2023 Jan 01;552:215981

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 36341997

    View Full Text